vs
FiscalNote Holdings, Inc.（NOTE）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是FiscalNote Holdings, Inc.的1.4倍（$30.3M vs $22.2M），REGENXBIO Inc.同比增速更快（43.0% vs -24.7%），FiscalNote Holdings, Inc.自由现金流更多（$-1.9M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -16.8%）
FiscalNote Holdings, Inc.（常称FiscalNote）是一家上市的软件数据与传媒企业，总部位于美国华盛顿特区，2013年由三位创始人创立。核心业务为通过政府关系管理服务FiscalNote GRM提供软件工具、平台、数据服务与资讯，同时依托人工智能平台分析美国待审议法案相关内容。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NOTE vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$22.2M
营收增速更快
RGNX
高出67.7%
-24.7%
自由现金流更多
NOTE
多$50.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-16.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $22.2M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -83.7% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | -24.7% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $-2.81 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NOTERGNX
| Q4 25 | $22.2M | $30.3M | ||
| Q3 25 | $22.4M | $29.7M | ||
| Q2 25 | $23.3M | $21.4M | ||
| Q1 25 | $27.5M | $89.0M | ||
| Q4 24 | $29.5M | $21.2M | ||
| Q3 24 | $29.4M | $24.2M | ||
| Q2 24 | $29.2M | $22.3M | ||
| Q1 24 | $32.1M | $15.6M |
净利润NOTERGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $-24.9M | $-61.9M | ||
| Q2 25 | $-13.3M | $-70.9M | ||
| Q1 25 | $-4.3M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $-14.9M | $-59.6M | ||
| Q2 24 | $-12.8M | $-53.0M | ||
| Q1 24 | $50.6M | $-63.3M |
毛利率NOTERGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率NOTERGNX
| Q4 25 | -83.7% | -190.0% | ||
| Q3 25 | -43.4% | -176.3% | ||
| Q2 25 | -31.9% | -296.3% | ||
| Q1 25 | -50.0% | 13.6% | ||
| Q4 24 | -19.4% | -242.1% | ||
| Q3 24 | -23.1% | -256.6% | ||
| Q2 24 | -27.2% | -251.3% | ||
| Q1 24 | -35.6% | -408.8% |
净利率NOTERGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | -110.8% | -208.3% | ||
| Q2 25 | -57.0% | -331.8% | ||
| Q1 25 | -15.4% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | -50.7% | -246.3% | ||
| Q2 24 | -43.6% | -237.7% | ||
| Q1 24 | 157.6% | -405.4% |
每股收益（稀释后）NOTERGNX
| Q4 25 | $-2.81 | $-1.30 | ||
| Q3 25 | $-1.73 | $-1.20 | ||
| Q2 25 | $-0.08 | $-1.38 | ||
| Q1 25 | $-0.03 | $0.12 | ||
| Q4 24 | $1.88 | $-0.99 | ||
| Q3 24 | $-1.33 | $-1.17 | ||
| Q2 24 | $-0.09 | $-1.05 | ||
| Q1 24 | $0.37 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $26.3M | $230.1M |
| 总债务越低越好 | $128.4M | — |
| 股东权益账面价值 | $62.0M | $102.7M |
| 总资产 | $255.1M | $453.0M |
| 负债/权益比越低杠杆越低 | 2.07× | — |
8季度趋势，按日历期对齐
现金及短期投资NOTERGNX
| Q4 25 | $26.3M | $230.1M | ||
| Q3 25 | $31.2M | $274.2M | ||
| Q2 25 | $38.5M | $323.3M | ||
| Q1 25 | $46.3M | $267.9M | ||
| Q4 24 | $34.6M | $234.7M | ||
| Q3 24 | $32.7M | $255.5M | ||
| Q2 24 | $37.7M | $290.4M | ||
| Q1 24 | $43.6M | $338.7M |
总债务NOTERGNX
| Q4 25 | $128.4M | — | ||
| Q3 25 | $131.5M | — | ||
| Q2 25 | $116.7M | — | ||
| Q1 25 | $118.0M | — | ||
| Q4 24 | $147.1M | — | ||
| Q3 24 | $152.2M | — | ||
| Q2 24 | $145.9M | — | ||
| Q1 24 | $153.0M | — |
股东权益NOTERGNX
| Q4 25 | $62.0M | $102.7M | ||
| Q3 25 | $75.5M | $161.5M | ||
| Q2 25 | $95.1M | $213.7M | ||
| Q1 25 | $98.7M | $274.2M | ||
| Q4 24 | $97.8M | $259.7M | ||
| Q3 24 | $98.5M | $301.4M | ||
| Q2 24 | $106.9M | $348.3M | ||
| Q1 24 | $106.1M | $390.7M |
总资产NOTERGNX
| Q4 25 | $255.1M | $453.0M | ||
| Q3 25 | $273.9M | $525.2M | ||
| Q2 25 | $288.3M | $581.0M | ||
| Q1 25 | $299.7M | $490.9M | ||
| Q4 24 | $326.2M | $466.0M | ||
| Q3 24 | $337.9M | $519.1M | ||
| Q2 24 | $346.3M | $569.4M | ||
| Q1 24 | $357.8M | $629.2M |
负债/权益比NOTERGNX
| Q4 25 | 2.07× | — | ||
| Q3 25 | 1.74× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.20× | — | ||
| Q4 24 | 1.50× | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 1.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-279.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-1.9M | $-52.8M |
| 自由现金流率自由现金流/营收 | -8.7% | -174.0% |
| 资本支出强度资本支出/营收 | 7.4% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.6M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NOTERGNX
| Q4 25 | $-279.0K | $-52.3M | ||
| Q3 25 | $-8.3M | $-56.0M | ||
| Q2 25 | $-6.2M | $-49.3M | ||
| Q1 25 | $3.3M | $33.6M | ||
| Q4 24 | $-1.3M | $-31.6M | ||
| Q3 24 | $-3.0M | $-40.5M | ||
| Q2 24 | $-3.7M | $-45.5M | ||
| Q1 24 | $2.7M | $-55.5M |
自由现金流NOTERGNX
| Q4 25 | $-1.9M | $-52.8M | ||
| Q3 25 | $-10.4M | $-56.5M | ||
| Q2 25 | $-7.7M | $-49.7M | ||
| Q1 25 | $1.3M | $32.6M | ||
| Q4 24 | $-3.4M | $-32.7M | ||
| Q3 24 | $-5.4M | $-40.9M | ||
| Q2 24 | $-6.5M | $-46.0M | ||
| Q1 24 | $1.0M | $-56.0M |
自由现金流率NOTERGNX
| Q4 25 | -8.7% | -174.0% | ||
| Q3 25 | -46.2% | -189.9% | ||
| Q2 25 | -33.0% | -232.8% | ||
| Q1 25 | 4.7% | 36.6% | ||
| Q4 24 | -11.4% | -154.2% | ||
| Q3 24 | -18.4% | -168.9% | ||
| Q2 24 | -22.1% | -206.2% | ||
| Q1 24 | 3.3% | -358.5% |
资本支出强度NOTERGNX
| Q4 25 | 7.4% | 1.7% | ||
| Q3 25 | 9.3% | 1.7% | ||
| Q2 25 | 6.4% | 1.8% | ||
| Q1 25 | 7.2% | 1.2% | ||
| Q4 24 | 6.8% | 5.1% | ||
| Q3 24 | 8.3% | 1.3% | ||
| Q2 24 | 9.4% | 2.1% | ||
| Q1 24 | 5.3% | 3.6% |
现金转化率NOTERGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.05× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NOTE
| Subscription | $21.2M | 95% |
| Advisory Advertising And Other | $1.0M | 5% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
